glp-1 for binge eating disorder Agonist Disorder: Evidence and Safety GLP-1 Therapy: An Emerging Tool

Weight loss Available in NZ = Liraglutide high dose (Saxenda, daily injection) Self-funding needed ($500-600/month) Not available in NZ = Semaglutide (Ozempic, Wegovy) or Tirzepatide (Mounjaro), as of May 2023 Side effects, particularly upper gastrointestinal, are common with GLP-1 agonist initiation

Research models where BPC-157 showed activity: Esophageal, gastric, and duodenal ulcers NSAID-induced small intestinal damage Colonic inflammation and ulceration Post-surgical anastomosis healing GI fistula closure In anastomosis research, BPC-157 improved healing in esophagogastric, jejunoileal, and colocolonic surgical connections

This brings us to the burgeoning field of needleless injections, proposing a compelling solution for individuals grappling with pernicious anaemia

Many Americans May Need More Potassium White Plains, New York, November 15, 2016 During a recent analysis of potassium supplements sold in the U.S

In future treatments, a potential direction could be to assess the risk of mitochondrial dysfunction more accurately for targeted therapy

Whether youre dealing with weight challenges, autoimmune conditions, or simply curious about cutting-edge solutions, this episode is packed with life-changing insights you wont want to miss